Physician profile
Jordan Goad
NPI 1639560857
$14,638.16
in general payments reported to CMS, 2019-2025
28 companies · $4,370 in 2025
The $4,370 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,781 · 2022: $2,303 · 2023: $2,584 · 2024: $3,600 · 2025: $4,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,294.58 |
| Education | $259.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,533.92 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,291.19 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $1,215.08 | 2021-2025 | Tremfya, Stelara, Remicade |
| Leo Pharma INC. | $1,149.26 | 2021-2025 | Adbry, Anzupgo |
| Amgen INC. | $914.36 | 2021-2025 | Otezla, Otezla, Enbrel |
| Novartis Pharmaceuticals Corporation | $790.14 | 2021-2025 | |
| Ucb, INC. | $743.58 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $697.46 | 2021-2025 | Taltz, Ebglyss, Zepbound |
| Sun Pharmaceutical Industries INC. | $691.52 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| E.R. Squibb & Sons, L.L.C. | $600.91 | 2022-2025 | Sotyktu |
| Incyte Corporation | $591.61 | 2021-2025 | Opzelura |
| Genzyme Corporation | $571.92 | 2022-2025 | |
| Dermavant Sciences, INC. | $534.27 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $380.94 | 2023-2025 | Spevigo |
| Galderma Laboratories, L.P. | $283.88 | 2021-2025 | Nemluvio |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $166.64 | 2023-2025 | Zoryve |
| Organon LLC | $160.96 | 2025 | Vtama |
| Kyowa Kirin, INC. | $54.48 | 2023 | Poteligeo |
| Almirall LLC | $49.55 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $47.80 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.48 | 2024-2025 | Jublia, Cabtreo, Arazlo |
| Epi Health, LLC | $29.84 | 2021-2022 | |
| Revance Therapeutics, INC. | $21.36 | 2025 | Daxxify |
| Vyne Pharmaceuticals INC. | $19.09 | 2021 | |
| Pfizer INC. | $16.99 | 2022 | |
| Cipher Pharmaceuticals US LLC | $14.68 | 2025 | Spinosad, Natroba |
| Fresenius Kabi USA, LLC | $14.20 | 2023 | Idacio |
| Stemline Therapeutics INC. | $12.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Goad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.